Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols

[1]  T. Naoe,et al.  Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group , 2017, Supportive Care in Cancer.

[2]  Georg Peters,et al.  Coagulase-Negative Staphylococci , 2005 .

[3]  Â. Maiolino,et al.  Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance , 2013, BMC Infectious Diseases.

[4]  E. Copelan,et al.  Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia , 2012, Stem cells.

[5]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2012, The Cochrane database of systematic reviews.

[6]  T. Naoe,et al.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. , 2011, Blood.

[7]  T. Naoe,et al.  A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML 201 Study , 2011 .

[8]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Naoe,et al.  Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group , 2011, International journal of hematology.

[10]  E. Jantunen,et al.  Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  M. Aapro,et al.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T. Naoe,et al.  Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study , 2010, International journal of hematology.

[13]  T. Naoe,et al.  Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group , 2009, International journal of hematology.

[14]  K. Mitani,et al.  A randomized, postremission comparison of four courses of standard‐dose consolidation therapy without maintenance therapy versus three courses of standard‐dose consolidation with maintenance therapy in adults with acute myeloid leukemia , 2005, Cancer.

[15]  Carlene A. Muto,et al.  A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.

[16]  R. Ohno,et al.  Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Masaoka.  Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Tanimoto,et al.  No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. , 1999, International journal of hematology.

[19]  J. Lau,et al.  Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Naoe,et al.  Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML‐87 study of the Japan adult leukemia study group , 1993 .

[21]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[22]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2005, The Cochrane database of systematic reviews.

[23]  T. Naoe,et al.  Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Tomonaga,et al.  Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). , 1992, Leukemia.